Filing Flows › Generate Biomedicines (GENB) › Recalls, complaints & regulation
Generate Biomedicines (GENB): clinical trials
Generate Biomedicines (GENB) beyond its filings: 5 active clinical trials.
Generate Biomedicines' latest quarter
Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year), net loss $67.3M, operating cash flow −$57.9M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Generate Biomedicines have?
5 active studies on ClinicalTrials.gov, 2 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.